Humalog Mix 75/25 Purple Book BLA 021017

BLA number
021017
Proprietary names
Humalog Mix 75/25
Proper names
insulin lispro protamine and insulin lispro
Applicant
Eli Lilly and Company
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Humalog Mix 75/25insulin lispro protamine and insulin lispro351(a)750UNITS/10ML (75UNITS/ML); 250UNITS/10ML (25UNITS/ML)Injectable SuspensionSubcutaneousMulti-Dose VialRxLicensed1999-12-22
002Humalog Mix 75/25insulin lispro protamine and insulin lispro351(a)225UNITS/3ML (75UNITS/ML); 75UNITS/3ML (25UNITS/ML)Injectable SuspensionSubcutaneousAutoinjectorRxLicensed2007-09-06
003Humalog Mix 75/25insulin lispro protamine and insulin lispro351(a)225UNITS/3ML (75UNITS/ML); 75UNITS/3ML (25UNITS/ML)Injectable SuspensionSubcutaneousAutoinjectorDiscLicensed1999-12-22

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-05-01R001Humalog Mix 75/25351(a)RxEli Lilly and Company
2020-05-01R002Humalog Mix 75/25351(a)RxEli Lilly and Company
2020-05-01R003Humalog Mix 75/25351(a)DiscEli Lilly and Company

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Humalog Mix 75/25351(a)RxLicensed1999-12-22
2020-05-01002Humalog Mix 75/25351(a)RxLicensed2007-09-06
2020-05-01003Humalog Mix 75/25351(a)DiscLicensed1999-12-22